A detailed history of Royal Bank Of Canada transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 29,940 shares of RVMD stock, worth $1.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,940
Previous 16,597 80.39%
Holding current value
$1.69 Million
Previous $644,000 110.56%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$36.92 - $47.94 $492,623 - $639,663
13,343 Added 80.39%
29,940 $1.36 Million
Q2 2024

Aug 14, 2024

BUY
$30.14 - $40.68 $307,608 - $415,180
10,206 Added 159.69%
16,597 $644,000
Q1 2024

Nov 05, 2024

SELL
$26.56 - $33.55 $271,071 - $342,411
-10,206 Reduced 61.49%
6,391 $205,000
Q1 2024

May 15, 2024

SELL
$26.56 - $33.55 $1.04 Million - $1.31 Million
-39,172 Reduced 85.97%
6,391 $205,000
Q4 2023

Feb 14, 2024

BUY
$18.35 - $34.12 $562,684 - $1.05 Million
30,664 Added 205.81%
45,563 $1.31 Million
Q3 2023

Nov 14, 2023

BUY
$25.17 - $35.05 $161,188 - $224,460
6,404 Added 75.39%
14,899 $412,000
Q2 2023

Aug 14, 2023

BUY
$20.28 - $27.0 $68,789 - $91,584
3,392 Added 66.47%
8,495 $227,000
Q1 2023

May 15, 2023

SELL
$20.76 - $30.09 $97,883 - $141,874
-4,715 Reduced 48.02%
5,103 $110,000
Q4 2022

Feb 14, 2023

BUY
$17.68 - $25.53 $153,992 - $222,366
8,710 Added 786.1%
9,818 $233,000
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $9,655 - $14,378
553 Added 99.64%
1,108 $22,000
Q2 2022

Aug 15, 2022

SELL
$14.54 - $27.17 $47,909 - $89,525
-3,295 Reduced 85.58%
555 $11,000
Q1 2022

May 16, 2022

BUY
$17.31 - $26.4 $9,174 - $13,992
530 Added 15.96%
3,850 $98,000
Q4 2021

Feb 14, 2022

BUY
$24.35 - $33.7 $38,107 - $52,740
1,565 Added 89.17%
3,320 $84,000
Q3 2021

Nov 15, 2021

BUY
$23.95 - $33.41 $42,032 - $58,634
1,755 New
1,755 $48,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $4.95B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.